Bristol-Myers will sell Opdivo in China at half of US cost, setting precedent for checkpoint wave — report
Bristol-Myers Squibb is continuing to set precedents in China with Opdivo, the first PD-1/L1 checkpoint approved in the country, as it reportedly prices the drug at around $84,000 per year — about half of its list price in the US.
A 100mg/10ml vial of Opdivo will cost around $1,352 (RMB 9260) while the 40mg/4ml vial comes in at $670 (RMB 4591), according to Chinese financial news outlet Caixin. The recommended dosage is 240 mg every two weeks or 480 mg every four weeks.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.